66J Stock Overview
Amniotics AB (publ) develops stem cell-based therapeutics to treat severe life-threatening diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Amniotics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.0002 |
| 52 Week High | kr0.01 |
| 52 Week Low | kr0.0002 |
| Beta | 0.54 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -97.22% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| 66J | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.2% | 2.0% |
| 1Y | -97.2% | -25.4% | 5.9% |
Return vs Industry: 66J underperformed the German Biotechs industry which returned -25.4% over the past year.
Return vs Market: 66J underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 66J volatility | |
|---|---|
| 66J Average Weekly Movement | 116.6% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 66J's share price has been volatile over the past 3 months.
Volatility Over Time: 66J's weekly volatility has decreased from 153% to 117% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 6 | Marcus Larsson | www.amniotics.com |
Amniotics AB (publ) develops stem cell-based therapeutics to treat severe life-threatening diseases. The company’s lead drug candidate is PulmoStem for the treatment of lung disease. It also develops CogniStem for the treatment of CNS indications; NephroStem for the treatment of kidney-specific indications; CutiStem for the treatment of dermatological indications; and AMNI-NK003.
Amniotics AB (publ) Fundamentals Summary
| 66J fundamental statistics | |
|---|---|
| Market cap | €842.69k |
| Earnings (TTM) | -€2.64m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs 66J overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 66J income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr30.87m |
| Earnings | -kr30.87m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 20, 2024
| Earnings per share (EPS) | -0.011 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 66J perform over the long term?
See historical performance and comparison